RET-Rearranged Lung Adenocarcinomas with Lymphangitic Spread, Psammoma Bodies, and Clinical Responses to Cabozantinib Sanjay Mukhopadhyay, MD, Nathan.

Slides:

Advertisements

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Advertisements

Jeffrey Bradley, MD Journal of Thoracic Oncology

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

ALK FISH and IHC: You Cannot Have One without the Other

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Y-L Chang, MD, C-T Wu, MD, Y-C Lee, MD, PhD

Waleed Brinjikji, MD, Jennifer M. Boland Froemming, MD, William P

Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH /RO )

Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm Heounjeong Go, MD, PhD, Dong-Wan Kim,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Resection of Mucinous Lung Adenocarcinoma Presenting with Intractable Bronchorrhea Motoshi Takao, MD, PhD, Takehiro Takagi, MD, Hitoshi Suzuki, MD, PhD,

Characterization of Pneumonitis in Patients with Advanced Non-small Cell Lung Cancer Treated with Everolimus (RAD001) Dorothy A. White, MD, Lawrence.

A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer Patrizia Viola, MD, Manisha Maurya,

NA Journal of Thoracic Oncology

Electronic Updates for JTO Readers

Hedgehog Signaling Pathway and Lung Cancer

Primary Pulmonary NUT Midline Carcinoma: Clinical, Radiographic, and Pathologic Characterizations Lynette M. Sholl, MD, Mizuki Nishino, MD, Saraswati.

The Moth-Eaten Lung Journal of Thoracic Oncology

Radiographic Imaging of Bronchioloalveolar Carcinoma: Screening, Patterns of Presentation and Response Assessment David R. Gandara, MD, Denise Aberle,

Successful Crizotinib Retreatment after Crizotinib-Induced Interstitial Lung Disease Satoru Yanagisawa, MD, PhD, Akira Inoue, MD, PhD, Akira Koarai, MD,

Radiological Changes After Stereotactic Radiotherapy for Stage I Lung Cancer Max Dahele, MBChB, MSc, David Palma, MD, Frank Lagerwaard, MD, PhD, Ben Slotman,

Hepatoid Carcinoma of the Lung with Anaplastic Lymphoma Kinase Gene Rearrangement Sean Khozin, MD, Mark J. Roth, MD, Arun Rajan, MD, Karen Smith, MD,

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Esophageal Ultrasound-Controlled Fine Needle Aspiration for Staging of Mediastinal Lymph Nodes in Patients with Resectable Lung Cancer: Do We Always See.

The Central Nervous System as a Sanctuary Site in ALK-Positive Non–Small-Cell Lung Cancer Justin F. Gainor, MD, Sai-Hong Ignatius Ou, MD, PhD, Jennifer.

Tracheal Glomus Tumor Successfully Resected With Rigid Bronchoscopy: A Case Report Flavio Colaut, MD, Lamberto Toniolo, MD, Antonio Scapinello, MD, Maurizia.

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

Kiran Devisetty, MD, Joseph K. Salama, MD Journal of Thoracic Oncology

Effective Treatment with Icotinib in Primary Adenoid Cystic Carcinoma of the Lung with Liver Metastasis Zhengbo Song, MD, Wei Wu, MD, Yiping Zhang, MD

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Jessica J. Lin, MD, Elizabeth Kennedy, BA, Lecia V

Vamsidhar Velcheti, MD, Manmeet Ahluwalia, MD

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Frequency of Lymph Node Metastasis According to the Size of Tumors in Resected Pulmonary Adenocarcinoma with a Size of 30 mm or Smaller Yangki Seok,

High MET Receptor Expression But Not Gene Amplification in ALK 2p23 Rearrangement Positive Non–Small-Cell Lung Cancer Yan Feng, MD, Eugen C. Minca, MD,

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

Mitotic Inhibitors Journal of Thoracic Oncology

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Drug Interaction Between Complementary Herbal Medicines and Gefitinib

Lung Adenocarcinoma with Concurrent Exon 19 EGFR Mutation and ALK Rearrangement Responding to Erlotinib Sanjay Popat, MRCP, PhD, Alexandra Vieira de.

Jeffrey Bradley, MD Journal of Thoracic Oncology

Fetal Adenocarcinoma of the Lung in a 25-Year-Old Woman

MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next- Generation Sequencing and Successfully Treated with a MET Inhibitor Carrie.

Beware of the “Bronchocele,” Particularly in Patients with a History or Risk Factors for a Mucinous Carcinoma: A Response to the Article “Resection of.

Phase I Study of Lenalidomide in Solid Tumors

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Two Generations of Light/Never-Smokers With Advanced Adenocarcinoma of the Lung with Durable Responses to Erlotinib Nathan A. Pennell, MD, PhD, Lihong.

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Antiangiogenesis Induced Tumor Cavitation in Lung Cancer

Manoj P. Menon, MD, MPH, Keith D. Eaton, MD, PhD

Genetic Changes in Squamous Cell Lung Cancer: A Review

Recurrent Primary Synovial Sarcoma of the Chest Wall

Metastatic Lung Cancer to the Pancreas

Intrathoracic Desmoid Tumor: Brief Report and Review of Literature

Todd J. Carpenter, MD, Kenneth E. Rosenzweig, MD

Cristiano Rampinelli, MD, Vittoria Vecchi, MD, Massimo Bellomi, MD

A Rare Cause of Multiple Cavitary Nodules

Journal of Thoracic Oncology

Christina S. Baik, MD, MPH, Marc C. Chamberlain, MD, Laura Q. Chow, MD

Tumor Lysis Syndrome in Limited-Stage Small-Cell Lung Cancer

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

David Garfield, MD Journal of Thoracic Oncology

Lack of FDG Uptake in Small Cell Carcinoma Associated with ANNA-1 Positive Paraneoplastic Autonomic Neuropathy Matthew S. Block, MD, PhD, Robert Vassallo,

Patterns-of-Care for Thoracic Stereotactic Body Radiotherapy among Practicing Radiation Oncologists in the United States Megan E. Daly, MD, Julian R.

ALK Status Testing in Non–Small-Cell Lung Carcinoma by FISH on ThinPrep Slides with Cytology Material Eugen C. Minca, MD, PhD, Christopher P. Lanigan,

A Review of First-Line Treatment for Small-cell Lung Cancer

Secondary Resistance to Erlotinib: Acquired T790M Mutation and Small-Cell Lung Cancer Transformation in the Same Patient Vincent Fallet, MD, Anne-Marie.

Presentation transcript:

RET-Rearranged Lung Adenocarcinomas with Lymphangitic Spread, Psammoma Bodies, and Clinical Responses to Cabozantinib Sanjay Mukhopadhyay, MD, Nathan A. Pennell, MD, Siraj M. Ali, MD, PhD, Jeffrey S. Ross, MD, Patrick C. Ma, MD, MSc, Vamsidhar Velcheti, MD Journal of Thoracic Oncology Volume 9, Issue 11, Pages 1714-1719 (November 2014) DOI: 10.1097/JTO.0000000000000323 Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Radiologic features and responses to RET inhibitor (cabozantinib) therapy in RET-rearranged lung adenocarcinomas. A–C, case 1. A, Bilateral reticulonodular opacities with solid and cavitary nodules in a lymphangitic distribution. PET-CT at presentation (B) and 1 month after cabozantinib therapy (C), demonstrating decrease in size and FDG avidity of nodules. D–E, case 2. CT scan at presentation (D) and 1 month after cabozantinib therapy (E), showing a decrease in size of the confluent right infrahilar mass and adenopathy involving the central right middle lobe, development of focal cavitation, and improvement in patency of the right middle lobe bronchus. Journal of Thoracic Oncology 2014 9, 1714-1719DOI: (10.1097/JTO.0000000000000323) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Histologic features of lung adenocarcinomas with RET rearrangements. A, Case 1. Psammoma bodies within solid-pattern tumor. B, Case 3. Tumor cells and psammoma bodies within a lymphatic. C, Case 4. High-grade nuclei, intranuclear cytoplasmic inclusion (top right), and a psammoma body (top center). D, Case 1. Mucinous cribriform pattern. E, Case 2. Signet-ring cells. Psammoma bodies were also present (not shown). F, Case 4. Large intracytoplasmic vacuoles. Journal of Thoracic Oncology 2014 9, 1714-1719DOI: (10.1097/JTO.0000000000000323) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions